Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | BA3021 |
Synonyms | |
Therapy Description |
BA3021 (CAB-ROR2-ADC) is a conditionally active anti-ROR2 antibody in conjugation with a cytotoxic agent that preferentially binds and delivers cytotoxicity to Ror2-expressing cells in tumors, therefore exhibits anti-tumor activity (Proceedings of the AACR, Apr 2018, Vol 59, Abstract 833). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BA3021 | CAB-ROR2-ADC|BA 3021 | BA3021 (CAB-ROR2-ADC) is a conditionally active anti-ROR2 antibody in conjugation with a cytotoxic agent that preferentially binds and delivers cytotoxicity to Ror2-expressing cells in tumors, therefore exhibits anti-tumor activity (Proceedings of the AACR, Apr 2018, Vol 59, Abstract 833). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03504488 | Phase Ib/II | BA3021 | CAB-ROR2-ADC Safety and Efficacy Study in Patients With Solid Tumors | Recruiting | USA | 2 |